I whakaputaina te rongoā whakakotahi Pyrotinib mō te mate pukupuku ū HER2 pai ki roto i te STTT of Nature

I te 29 o Hānuere, 2025, i whakaputahia e tētahi rōpū rangahau Hainamana tētahi tuhinga ko te taitara "Neoadjuvant pyrotinib and trastuzumab in HER2 positive breast cancer with no early response (NeoPaTHer): effectiveness, safety, and biomarker analysis of a prospective, multicenter, response adapted study" i roto i te puka "Signal Transduction and Targeted Therapy".

Ko te mate pukupuku ū epidermal growth factor receptor 2 (HER2)-positive, e pā ana ki te ~15% ki te 25% o ngā mate pukupuku ū katoa, e mōhiotia ana he momo motuhake, he momo pukuriri hoki. E tohuhia ana e te nui rawa o te HER2, he receptor tyrosine kinase transmembrane e whakatairanga ana i te tipu me te oranga o ngā pūtau mate pukupuku. He nui ake te tūponotanga o te hokinga mai me te mate o ngā tūroro he mate pukupuku ū HER2-positive ki te hunga he momo mate pukupuku ū kē atu, ā, he tino uaua ki te rongoā. Heoi, kua tino rerekē te āhua o te maimoatanga mate pukupuku ū HER2-positive i ngā tekau tau e rua kua pahure ake nei, nā te whakaurunga o ngā maimoatanga HER2-targeted. Ina koa, ko te taenga mai o trastuzumab kua tino whakarerekē i te ara o te mate pukupuku ū HER2-positive mai i te mate tino mate ki tētahi mate ngāwari ake te whakahaere me te iti ake o ngā putanga kino.

I waenganui i a Oketopa 2020 me Maehe 2022, e 129 ngā tūroro katoa mai i ngā hōhipera e rima i whakaurua ki tēnei rangahau. O ngā tūroro 129 i whakaurua, e 62 (48.1%) i tautuhia ko rātou ngā kaiwhakautu MRI (rōpū A), e 26 ngā kāore i whakautu i haere tonu me ētahi atu huringa TCbH e whā (rōpū B), ā, e 41 ngā kāore i whakautu i whiwhi i ētahi atu pyrotinib (rōpū C). Ko te reiti tpCR he 30.6% (95% CI: 20.6–43.0%) i roto i te rōpū A, 15.4% (95% CI: 6.2–33.5%) i roto i te rōpū B, me te 29.3% (95% CI: 17.6–44.5%) i roto i te rōpū C. I whakaatuhia e ngā tātaritanga whakatauranga logistic maha-taurangi he rite tonu te tūponotanga ki te whakatutuki i te tpCR i waenga i ngā rōpū A me C (ōwehenga ōwehenga = 1.04, 95% CI: 0.40–2.70). Kāore i kitea he pānga kino hou me te tāpiri o te pyrotinib. Ko ngā tūroro he whakarerekētanga tahi o te TP53 me te PIK3CA i whakaatu i ngā reiti iti ake o te urupare ā-wāhanga wawe ki te hunga kāore he whakarerekētanga ira kotahi, he whakarerekētanga ira kotahi rānei (36.0% vs. 60.0%, P = 0.08). E kī ana ēnei kitenga ko te tāpiri i te pyrotinib ka whai hua pea ki ngā tūroro kāore e aro ki te neoadjuvant trastuzumab me te chemotherapy. Me whakahaere tonu he rangahau hei tautuhi i ngā tohu koiora e tohu ana i ngā painga o te tāpiri o te pyrotinib ki ngā tūroro.

I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.

Tau Waea：4008803716

Email：myimmnet@163.com

Ngā Tohutoro

https://www.nature.com/articles/s41392-025-02138-6